Business Description
Vivozon Pharmaceutical Co Ltd
ISIN : KR7082800004
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.43 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.4 | |||||
Debt-to-EBITDA | 14.14 | |||||
Interest Coverage | 1.24 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | -0.66 | |||||
Beneish M-Score | -2.25 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.7 | |||||
3-Year EPS without NRI Growth Rate | 74 | |||||
3-Year Book Growth Rate | -16.8 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 13.16 | |||||
9-Day RSI | 24.48 | |||||
14-Day RSI | 32.76 | |||||
6-1 Month Momentum % | 1.33 | |||||
12-1 Month Momentum % | -21.93 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.7 | |||||
Quick Ratio | 0.5 | |||||
Cash Ratio | 0.27 | |||||
Days Inventory | 117.74 | |||||
Days Sales Outstanding | 52.14 | |||||
Days Payable | 78.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18.8 | |||||
Shareholder Yield % | 19.33 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 43.44 | |||||
Operating Margin % | 5.03 | |||||
Net Margin % | -4.65 | |||||
FCF Margin % | -5.09 | |||||
ROE % | -3.14 | |||||
ROA % | -1.85 | |||||
ROIC % | 1.88 | |||||
ROC (Joel Greenblatt) % | -0.85 | |||||
ROCE % | -0.26 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.89 | |||||
PB Ratio | 1.29 | |||||
Price-to-Tangible-Book | 1.44 | |||||
Price-to-Operating-Cash-Flow | 45.97 | |||||
EV-to-EBIT | -557.55 | |||||
EV-to-EBITDA | 54.12 | |||||
EV-to-Revenue | 2.2 | |||||
EV-to-FCF | -43.29 | |||||
Price-to-Projected-FCF | 22.39 | |||||
Price-to-Median-PS-Value | 1.38 | |||||
Earnings Yield (Greenblatt) % | -0.18 | |||||
FCF Yield % | -2.72 |